Svatek RS - Search Results

1

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Shore ND, et al. Among authors: svatek rs. J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. J Clin Oncol. 2017. PMID: 28834453 Free PMC article. Clinical Trial.

2

Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?

Svatek RS, Lee D, Lotan Y. Svatek RS, et al. Urology. 2005 Jul;66(1):65-8. doi: 10.1016/j.urology.2005.02.003. Urology. 2005. PMID: 15992876

3

Application of novel hemostatic agent during laparoscopic partial nephrectomy.

Margulis V, Matsumoto ED, Svatek R, Kabbani W, Cadeddu JA, Lotan Y. Margulis V, et al. J Urol. 2005 Aug;174(2):761-4. doi: 10.1097/01.ju.0000164727.53999.fe. J Urol. 2005. PMID: 16006972

4

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

5

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

6

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Among authors: svatek rs. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

7

The cost of prostate cancer chemoprevention: a decision analysis model.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896037

8

The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma.

Svatek RS, Lotan Y, Herman MP, Duchene DA, Sagalowsky AI, Cadeddu JA. Svatek RS, et al. J Urol. 2006 Oct;176(4 Pt 1):1321-5; discussion 125. doi: 10.1016/j.juro.2006.06.008. J Urol. 2006. PMID: 16952621

9

Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours.

Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, Cadeddu JA. Stern JM, et al. BJU Int. 2007 Aug;100(2):287-90. doi: 10.1111/j.1464-410X.2007.06937.x. BJU Int. 2007. PMID: 17617136

10

Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.

Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, Roehrborn CG. Shariat SF, et al. Among authors: svatek rs. BJU Int. 2008 Jan;101(2):232-7. doi: 10.1111/j.1464-410X.2007.07181.x. Epub 2007 Sep 13. BJU Int. 2008. PMID: 17868422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page